The Unmet Clinical Need: Optimizing Covered Device Performance through Smarter Membrane Design

In today’s cardiovascular , structural heart and neurovascular device landscape, innovation doesn’t stop with the stent or frame , it depends on how the cover performs in the body. Medibrane partners with medical device innovators to solve the persistent biological and mechanical challenges that limit covered stents, occluders, and flow‑modulating devices.

The Clinical Challenge: Healing vs. Hemodynamics

A polymer cover can protect, seal, or control blood flow, yet it can also disrupt the body’s natural healing and blood dynamics.

For many device developers, the key is achieving the right balance ,enabling tissue integration and re‑endothelialization without provoking thrombosis, occlusion, or stiffness.

Medibrane’s mission is to transform the traditional “passive barrier” into an active component of healing , helping our partners design devices that synchronize biological response with mechanical performance.

1. The “Desert Problem”: Delayed Endothelialization

Bio‑inert membranes like ePTFE or dense polyurethane can act as shields, preventing endothelial cells from reaching the metal struts.

The result is delayed healing and increased risk of very late stent thrombosis (VLST), as the surface remains “naked” to circulating blood for months.

Medibrane addresses this through engineered biocompatibility — using surface topography, designed porosity, and selective biofunctionalization to promote rapid endothelialization while maintaining blood‑tight sealing.

2. The Wall‑Effect and Edge Stenosis

Covered stents often create a flow discontinuity at the transition between covered and uncovered segments.

This “wall effect” fosters turbulence, low shear stress, and neointimal hyperplasia , or even the unwanted “jailing” of side branches.

Medibrane refines edge design and surface flow behavior, developing membrane configurations that support smoother flow and reduce local turbulence.

3. Device‑Related Thrombosis in Occluders and Shunt Devices

In devices like occluders or interatrial shunts, both healing extremes are dangerous: under‑healing raises DRT and stroke risk, while over‑healing can seal the flow path entirely.

Medibrane enables controlled healing by adjusting pore size, membrane architecture, and surface energy to achieve predictable tissue response while preserving therapeutic flow.

4. Flow Diverters and Aneurysm Occlusion

Bare flow diverters may require up to six months for the aneurysm sac to fully occlude.

During the early 10‑day to 6‑month transition window, the aneurysm remains vulnerable ,a period where thrombus is immature and rupture or embolic events can still occur.

Medibrane collaborates with innovators to develop ultra‑thin, biocompatible covers and specialized surface treatments that stabilize intra‑aneurysmal clot formation and accelerate neointimal sealing , potentially shortening the vulnerability period and improving procedural safety.

5. Mechanical Reliability and Deliverability

Engineering tradeoffs further complicate device design:

• Profile–deliverability paradox: covers improve function but raise crossing profile.

• Elastic mismatch and delamination: metals and polymers deform differently during expansion.

• Membrane fatigue: millions of cardiac cycles can induce creep or pinholes.

Medibrane co‑optimizes polymer structure and metal compatibility to ensure flexible, fatigue‑resistant membranes that maintain integrity under dynamic cardiac and vascular loading.

6. Tailored Solutions for Next‑Generation Implants

Every device faces its own performance envelope —,from high‑shear blood pumps to flow‑restricting IVC systems and interatrial shunts prone to over‑healing.

Medibrane supports each partner through material selection, mechanical co‑design, and prototype development to align cover function with the intended clinical outcome.

At Medibrane, we don’t just make medical covers — we engineer the interface between blood, tissue, and device.

Through smarter membrane design, we help innovators close the gap between clinical need and device performance.

References :

1. Kim U, Kim D, Hong MK, et al. Delayed endothelialization after polytetrafluoroethylene‑covered stent implantation. Case report. PubMed. 2009.[pubmed.ncbi.nlm.nih]​

2. Biedermann JS, Zuber‑Johann F, Roffi M, et al. The jailed stent‑balloon bifurcation stenting technique. EuroIntervention. 2025.[pmc.ncbi.nlm.nih]​

3. Alkhouli M, Badhwar V, Holmes DR Jr, et al. Device‑related thrombus after left atrial appendage occlusion. J Am Coll Cardiol Intv. 2019.[pmc.ncbi.nlm.nih]​

4. Masri A, Kapadia SR, et al. Interatrial shunts: a promising therapy for HFpEF or disappointing mirage? Cardiac Interventions Today. 2025.[citoday]​

5. Qian Y, Geng H, Han W, et al. Impact of impeller speed adjustment interval on hemolysis in a blood pump. Artif Organs. 2024.[pmc.ncbi.nlm.nih]​

6. Kapelios CJ, Gkolfakis N, Giamouzis G, et al. Novel IVC Doraya catheter provides congestion relief in patients with acute heart failure. Front Cardiovasc Med. 2022.[pmc.ncbi.nlm.nih]​

7. Alkhouli M, Nkomo VT, et al. Interatrial shunt devices. Curr Cardiol Rep. 2023.[pmc.ncbi.nlm.nih]​

8. Rouchaud A, Brinjikji W, Lanzino G, et al. Intra‑aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow‑diverter treatment. AJNR Am J Neuroradiol. 2015.[pmc.ncbi.nlm.nih]​

9. Patel MR, Meier P, Abawi M, et al. Coronary sinus Reducer non‑responders: insights and perspectives. EuroIntervention. 2025.[eurointervention.pcronline]​

10. Armoiry X, et al. The evaluation of the flow re‑direction endoluminal device (FRED) for intracranial aneurysm treatment: mid‑term outcomes. J Neurointerv Surg. 2025.[pmc.ncbi.nlm.nih]​

11. Sharma RK, Bansal M, et al. Endoleak in covered CP stent causes procedural failure: a case report. Catheter Cardiovasc Interv. 2024.[pubmed.ncbi.nlm.nih]​

12. Nietlispach F, Meier B, Gafoor S, et al. Safety and feasibility of peri‑device leakage closure after left atrial appendage occlusion. JACC Clin Electrophysiol. 2021.[pmc.ncbi.nlm.nih]​

13. Takaya Y, Akagi T, Kijima Y, et al. Cardiac erosion after catheter closure of atrial septal defect. J Thorac Dis. 2014.[pmc.ncbi.nlm.nih]​

14. Osmancik P, Nietlispach F, et al. EHRA/EAPCI expert consensus statement on catheter‑based left atrial appendage occlusion. EuroIntervention. 2023.[eurointervention.pcronline]​

15. Aliaş A, Fernández‑Palacián C, Cambra FJ. Coronary stent fractures: an engineering approach (review). Engineering. 2013.[scirp]​

16. Arvanitis TN, Rathi V, et al. Endovascular detection of catheter‑thrombus contact by vacuum pressure. arXiv preprint.[arxiv]​

17. Yu H, Wang Y, Li Y, et al. Hemodynamic effects of stent‑induced straightening of parent artery in intracranial bifurcation aneurysms. Front Neurol. 2022.[pmc.ncbi.nlm.nih]​

18. Lapergue B, Blanc R, Gory B, et al. Risk of distal embolization with stent retriever thrombectomy and aspiration in a stroke model. Stroke. 2014.[pmc.ncbi.nlm.nih]​

19. Živčák J, Hudák R, et al. Fatigue analysis based on fatigue failure approach for cardiovascular stents made of L‑605 Co‑Cr alloy. Biomech Model Mechanobiol. 2023.[bura.brunel.ac]​

20. Alkhouli M, Busu T, Shah K, et al. Residual leaks post left atrial appendage occlusion. American College of Cardiology Review Article. 2022.[acc]​

About the Author

Elad Einav is a mechanical engineer specializing in polymeric membrane technologies for medical device applications. He holds a B.Sc. in Mechanical Engineering from the Technion – Israel Institute of Technology. With over a decade of experience, his work focuses on membrane material behavior, structure and morphology control, process development, and manufacturing methods for regulated medical environments. Founder of Medibrane,Airwaymedics,Biovo technologies and EndoGi medical.